Craft

Neurocrine UK

Revenue

£4.7 M

FY, 2022

Neurocrine UK Summary

Company Summary

Overview
Neurocrine UK (formerly known as Diurnal) is a pharmaceutical company creating therapeutic drugs for use in the endocrine area. It provides treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism.
Type
Subsidiary
Status
Active
Founded
2004
HQ
Cardiff, GB | view all locations
Website
https://uk.neurocrine.com/
Cybersecurity rating
Sectors

Key People

  • Sam Williams

    Sam Williams, Interim Chairman, Board Representative of IP Group Plc

  • Anders Harfstrand, Chairman

    • Richard Bungay

      Richard Bungay, Interim Chief Executive Officer, CFO and Director

    • Richard Ross

      Richard Ross, Chief Scientific Officer, Director

    LocationsView all

    1 location detected

    • Cardiff, Wales HQ

      United Kingdom

    Neurocrine UK Financials

    Summary Financials

    Revenue (FY, 2022)
    £4.7M
    Gross profit (FY, 2022)
    £3.8M
    Net income (FY, 2022)
    (£16.6M)
    Cash (FY, 2022)
    £16.5M
    EBIT (FY, 2022)
    (£19.3M)

    Footer menu